Geron Corporation Share Price Today: Live Updates & Key Insights

Geron Corporation share price today is $1.47, up -5.81%. The stock opened at $1.54 against the previous close of $1.55, with an intraday high of $1.5451 and low of $1.45.

Geron Corporation Share Price Chart

Geron Corporation

us-stock
To Invest in {{usstockname}}
us-stock

Geron Corporation Share Price Performance

$1.47 -0.0581(-5.81%) GERN at 23 Mar 2026 01:17 PM Biotechnology
Lowest Today 1.45
Highest Today 1.5451
Today’s Open 1.54
Prev. Close 1.55
52 Week High 2.01
52 Week Low 1.04
Day’s Range: Low 1.45 High 1.5451
52-Week Range: Low 1.04 High 2.01
1 day return -
1 Week return -12.08
1 month return -17.56
3 month return +8.17
6 month return +9.81
1 year return -16.61
3 year return -36.46
5 year return -18.48
10 year return -

Geron Corporation Institutional Holdings

RA Capital Management, LLC 9.96

BlackRock Inc 7.28

Deep Track Capital, LP 6.42

Vanguard Group Inc 5.57

Vivo Capital, LLC 4.25

State Street Corp 4.16

The Goldman Sachs Group Inc 3.33

Vanguard Total Stock Mkt Idx Inv 3.13

Soleus Capital Management, L.P. 2.70

ClearBridge Advisors, LLC 2.22

State Street® SPDR® S&P® Biotech ETF 2.14

iShares Russell 2000 ETF 2.05

Geode Capital Management, LLC 2.03

Eversept Partners, LP 1.97

Vestal Point Capital LP 1.77

Morgan Stanley - Brokerage Accounts 1.67

Citadel Advisors Llc 1.55

Aberdeen Group PLC 1.49

Fidelity Select Biotechnology 1.41

Nantahala Capital Management, LLC 1.41

Vanguard Explorer Inv 1.37

FMR Inc 1.26

UBS Group AG 1.21

Woodline Partners LP 1.17

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Fidelity Small Cap Index 0.84

ClearBridge Small Cap Growth 0.83

ClearBridge Small Cap Growth A 0.83

Deutsche Bank AG 0.80

Xtrackers MSCI World Swap ETF 1C 0.73

iShares Russell 2000 Growth ETF 0.71

iShares Biotechnology ETF 0.70

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

Belfius Equities Cure C Cap 0.44

Fidelity Extended Market Index 0.44

abrdn Healthcare Investors 0.44

Vanguard Russell 2000 ETF 0.41

Schwab US Small-Cap ETF™ 0.41

EdRF Healthcare A EUR 0.36

State St Russell Sm Cap® Indx SL Cl I 0.28

Geron Corporation Market Status

Strong Buy: 4

Buy: 2

Hold: 3

Sell: 0

Strong Sell: 0

Geron Corporation Fundamentals

Market Cap 935.20 M

PB Ratio 4.112

PE Ratio 0.0

Enterprise Value 692.86 M

Total Assets 570.54 M

Volume 39135225

Geron Corporation Company Financials

Annual Revenue FY25:183881000 183.9M, FY23:317000 0.3M, FY22:596000 0.6M, FY21:1393000 1.4M, FY20:253000 0.3M

Annual Profit FY25:179136000 179.1M, FY23:null 0.0M, FY22:596000 0.6M, FY21:1393000 1.4M, FY20:253000 0.3M

Annual Net worth FY25:-85782000 -85.8M, FY23:-174789000 -174.8M, FY22:-141033000 -141.0M, FY21:-120952000 -121.0M, FY20:-75610000 -75.6M

Quarterly Revenue Q4/2025:48015000 48.0M, Q3/2025:47227000 47.2M, Q2/2025:49036000 49.0M, Q1/2025:39603000 39.6M, Q3/2024:28271000 28.3M

Quarterly Profit Q4/2025:46709000 46.7M, Q3/2025:25114000 25.1M, Q2/2025:47846000 47.8M, Q1/2025:38397000 38.4M, Q3/2024:28209000 28.2M

Quarterly Net worth Q4/2025:-31144000 -31.1M, Q3/2025:-18428000 -18.4M, Q2/2025:-16375000 -16.4M, Q1/2025:-19835000 -19.8M, Q3/2024:-26447000 -26.4M

About Geron Corporation & investment objective

Company Information Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Organisation Biotechnology

Employees 258

Industry Biotechnology

CEO Mr. Harout Semerjian

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Geron Corporation FAQs

What is the share price of Geron Corporation today?

The current share price of Geron Corporation is $1.47.

Can I buy Geron Corporation shares in India?

Yes, Indian investors can buy Geron Corporation shares by opening an international trading and demat account with Motilal Oswal.

How to buy Geron Corporation shares in India?

You can easily invest in Geron Corporation shares from India by:

Can I buy fractional shares of Geron Corporation?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Geron Corporation?

Geron Corporation has a market cap of $935.20 M.

In which sector does Geron Corporation belong?

Geron Corporation operates in the Biotechnology sector.

What documents are required to invest in Geron Corporation stocks?

To invest, you typically need:

What is the PE and PB ratio of Geron Corporation?

The PE ratio of Geron Corporation is N/A and the PB ratio is 4.11.